Drug
Dolutegravir Sodium/Lamivudine clinical trials
- studies test it
- 8
- open now
- 3
- in phase 3
- 2
- first study started
- 2020
Keep track of what changes. Save the Dolutegravir Sodium/Lamivudine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 2
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 7
Fundacion SEIMC-GESIDA (1) · Charlotte-Paige Rolle, MD (1) · ViiV Healthcare (1) · Saskatchewan Health Authority - Regina Area (1) · Fundación Huésped (1) · Johns Hopkins University (1) · Societa' Italiana Di Malattie Infettive E Tropicali (1) · Thomas Benfield (1)
Often tested with
Tested in the same studies.
Dolutegravir (8) · Abacavir, dolutegravir, and lamivudine drug combination (1) · Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (1)
Studies
Open first, then newest update. How each study uses Dolutegravir Sodium/Lamivudine is read from its arms, and is right about nine times in ten.
Testing it · 8
- Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenRecruitingPhase 4Fundación HuéspedNCT07616739Written as Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
- Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentRecruitingPhase 3Johns Hopkins UniversityNCT06497465Written as Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]
- Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)Not yet recruitingPhase 4Saskatchewan Health Authority - Regina AreaNCT06580873Written as DOVATO
- Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to LamivudineCompletedPhase 2Fundacion SEIMC-GESIDANCT04880785Written as Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
- Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAFCompletedPhase 4Charlotte-Paige Rolle, MDNCT04585737Written as Dolutegravir / Lamivudine Pill
- A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult ParticipantsCompletedPhase 1ViiV HealthcareNCT04827134Written as DOVATO
- Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)Status unknownPhase 3Societa' Italiana Di Malattie Infettive E TropicaliNCT04979468Written as DOVATO
- Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir DisproxilStatus unknownPhase 4Thomas BenfieldNCT04903847Written as Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]